Siemens KD2 Linear Accelerators

The majority of treatments at the Indiana University Department of Radiation Oncology are carried out on two separate twin accelerators, the Siemens KD2 dual energy accelerators. The first KD2 linear accelerator replaced the departmentŐs Sagittaire and is housed in the same physical location. It was commissioned in July of 1994. With the added physical space brought on by construction in the department there was room for another identical machine within the new portion of the department. That KD2 linear accelerator was commissioned in October of 1995. The two machines are nearly identical and treatments on each machine can be interchanged without replanning or calibration. Each machine boasts ultramodern radiation therapy delivery features. Commissioned photon energies are six million volts as well as separate 15 million volt energy for more deep-seated tumors.

In addition, each machine has capability for multiple electron energies of six, nine, twelve, fifteen, and eighteen million electron volts. Each machine is integrated with computer software that networks throughout the physics/dosimetry section of the department. This allows a lack of translational error between treatment planning and delivery of the treatment. Each machine is equipped with interlocks that will not allow treatment to commence unless green flags are given by all important aspects of treatment. In addition, each machine has the capability of real time portal imaging with beamview. Beamview allows the physician or therapist to review the anatomy being treated with a low radiation exposure correlation between planning targets and actually delivered targets. Each accelerator is housed in an ultramodern treatment suite, which includes state-of-the-art patient monitoring equipment as well as hook-ups to required suction, oxygen, and anesthesia equipment.

The larger rooms for the KD2 linear accelerators also facilitate the treatment of total skin electron therapy. This therapy is useful for a select group of patients who require treatment for a diffuse skin lymphoma called mycosis fungoides.

Since commissioning, the two accelerators have become the mainstay of therapy for the department. They have operated efficiently and timely. Their similar characteristics have allowed the patients to be treated on either machine, thereby facilitating down time from each machine for scheduled maintenance without disrupting patient flow.

 

< back >